GlassScriptPhysician profile
Kari Suzanne Peeper
NPI 1730895111
$1,228.95
in general payments reported to CMS, 2019-2025
16 companies · $660 in 2025
The $660 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $110 · 2024: $459 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,228.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $241.39 | 2025 | Inspire |
| Lilly USA, LLC | $209.15 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $140.74 | 2024 | Breztri, Farxiga |
| Abbvie INC. | $110.39 | 2024-2025 | |
| Novo Nordisk INC | $98.85 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $97.56 | 2025 | |
| Astellas Pharma US INC | $70.60 | 2025 | Veozah |
| Exact Sciences Corporation | $45.00 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $38.21 | 2023-2024 | M-M-R II, Gardasil 9, Vaxneuvance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.62 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $32.49 | 2024-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.22 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.32 | 2024 | Jardiance |
| Corium, LLC | $19.98 | 2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $17.32 | 2025 | Fanapt, Hetlioz |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $16.11 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kari Peeper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.